Physician profile
Deepika Kunnath
NPI 1396240438
$1,460.90
in general payments reported to CMS, 2019-2025
25 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.45 · 2022: $434 · 2023: $432 · 2024: $256 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $184.54 | 2021-2024 | |
| Organon LLC | $156.83 | 2021-2024 | Nexplanon |
| Abbvie INC. | $146.16 | 2022-2023 | |
| Novo Nordisk INC | $121.91 | 2022-2024 | Wegovy, Saxenda |
| Astellas Pharma US INC | $121.29 | 2022-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $108.30 | 2024-2025 | Gemtesa, Myfembree |
| Boston Scientific Corporation | $76.46 | 2024-2025 | Ams 700, Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $60.69 | 2025 | |
| Lilly USA, LLC | $57.76 | 2023-2024 | Omvoh, Mounjaro |
| Mayne Pharma Commercial LLC | $54.78 | 2022-2024 | |
| Exact Sciences Corporation | $53.66 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $40.26 | 2022-2023 | Fasenra |
| Avion Pharmaceuticals | $34.78 | 2021-2023 | Balcoltra |
| Caris Mpi, INC. | $25.05 | 2025 | Mi Cancer Seek |
| Aspira Women'S Health INC | $24.76 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $24.60 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $24.29 | 2025 | Dupixent |
| Abbott Laboratories | $23.34 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.89 | 2025 | Jardiance |
| Dynavax Technologies Corporation | $20.21 | 2023 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.17 | 2024 | Xifaxan |
| Glaxosmithkline, LLC. | $16.85 | 2023 | Shingrix, Bexsero |
| Sage Therapeutics, LLC | $16.78 | 2022 | |
| Coopersurgical, INC. | $13.75 | 2023 | Endosee |
| Horizon Therapeutics Plc | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Kunnath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.